XOMA’s (XOMA) Buy Rating Reaffirmed at HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $123.00 price objective on the biotechnology company’s stock, up from their previous price objective of $117.00. HC Wainwright’s price objective indicates a potential upside of 268.26% from the stock’s current price.

Separately, StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th.

XOMA Stock Down 0.1 %

NASDAQ:XOMA traded down $0.05 during trading hours on Monday, reaching $33.40. 7,801 shares of the stock were exchanged, compared to its average volume of 22,034. The stock has a market cap of $393.55 million, a PE ratio of -9.60 and a beta of 0.90. XOMA has a twelve month low of $14.77 and a twelve month high of $35.00. The firm has a 50 day moving average of $29.37 and a 200 day moving average of $27.37. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

Insider Activity at XOMA

In other news, CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares in the company, valued at $1,047,621.05. The trade was a 38.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 7.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On XOMA

A number of hedge funds have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets raised its holdings in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of XOMA in the first quarter worth approximately $212,000. Rhumbline Advisers lifted its holdings in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares in the last quarter. Barclays PLC boosted its position in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 8,447 shares during the last quarter. Finally, Ellsworth Advisors LLC bought a new stake in XOMA during the third quarter worth $516,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.